Jones Trading analyst Debanjana Chatterjee reiterated a 'Buy' rating on Trevi Therapeutics (TRVI) and increased the price target from $24 to $28. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their assessment.
Jones Trading analyst Debanjana Chatterjee maintained a 'Buy' rating on Trevi Therapeutics (TRVI) and raised the price target from $24 to $28. This action signals increased confidence from the analyst in TRVI's future performance and valuation. For traders, this could be seen as a positive signal, potentially leading to short-term upward price momentum as investors react to the updated target. The long-term implication depends on whether the company's fundamentals align with the analyst's optimistic view. A key opportunity for traders is to capitalize on any immediate positive sentiment, while a risk is that the market may not fully embrace the new price target or that other factors could overshadow this analyst upgrade.